U.S. FDA APPROVES ZIIHERA® (ZANIDATAMAB-HRII) WITH AND WITHOUT TISLELIZUMAB PLUS CHEMOTHERAPY IN FIRST-LINE HER2+ ADVANCED GASTROESOPHAGEAL ADENOCARCINOMA

Reuters · 2d ago

Please log in to view news